Loading…
Employees: 5,627
Size Guangxi LiuYao (603368.SS) is a China Health Care company (Medical Distributors) with a market value of $994M, the 2307th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥17.11 on 6 Nov 2026.
Performance Over six months the shares gained 2.2%, against -6.8% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 1.7% over the last twelve months (peer median +4.1%); the operating margin is 4.6% (peer median 1.3%).
Valuation It trades at 9.9× forward earnings against a peer median of 16.4× (cheapest of 11).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.5 points above its cost of capital (5.2% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥21.3B | CN¥20.9B | CN¥21.1B | CN¥20.8B | CN¥19.0B |
| Revenue growth | — | -1% | +2% | +9% | — |
| Gross profit | CN¥2.30B | CN¥2.10B | CN¥2.18B | CN¥2.24B | CN¥1.96B |
| EBITDA | n/a | CN¥1.32B | CN¥1.46B | CN¥1.52B | CN¥1.34B |
| Net income | CN¥620M | CN¥709M | CN¥855M | CN¥850M | CN¥702M |
| Free cash flow | CN¥979M | CN¥931M | CN¥709M | CN¥421M | CN¥331M |
| Capital expenditure | CN¥171M | CN¥184M | CN¥148M | CN¥173M | CN¥183M |
| Total debt | CN¥5.58B | CN¥8.15B | CN¥7.47B | CN¥8.06B | CN¥7.16B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603368.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.4% | +0.8% | 3rd highest of 21 |
| 6-month return | +2.2% | -6.8% | 8th highest of 21 |
| Distance from 52-week high | -12.9% | -20.3% | 6th highest of 21 |
| Revenue growth (TTM) | +1.7% | +4.1% | 7th lowest of 21 |
| Operating margin | 4.6% | 1.3% | 5th highest of 21 |
| Forward P/E | 9.9× | 16.4× | cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | -9.5% | -0.4% | 3rd least demanding of 17 |
| Growth delivered (Del g) | +6.0% | +4.5% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | -15.5 pp | -6.2 pp | 3rd least demanding of 17 |
| ROIC minus cost of capital | +2.5 pp | +0.4 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 9.9× | -9.5% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 21.3× | -1.3% | +3.9% |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | n/a | n/a | n/a |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | n/a | n/a | n/a |
| Shanghai Haohai Biological Technology 688366.SS | China | $946M | -24% | -9% | -2% | 17.4× | 18.9% | +13.2% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 18.2× | -1.0% | +6.3% |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 46.5× | 21.8% | +29.9% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 14.2× | -5.9% | +1.2% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | n/a | -1.3% | +17.9% |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 15.3× | 5.0% | +8.1% |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 13.8× | -14.7% | +7.6% |
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | n/a | 0.3% | +1.0% |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 21.6× | -7.4% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | n/a | n/a | n/a |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | n/a | 14.4% | +7.5% |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 11.9× | -7.1% | +3.8% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | n/a | 12.2% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | n/a | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $475M | -60% | -22% | -1% | n/a | 59.0% | -7.8% |
| Suzuken 9987.T | Japan | $2.29B | -9% | +5% | 1% | 15.0× | -11.9% | +3.2% |
| Vital KSK 3151.T | Japan | $428M | +7% | +2% | 1% | n/a | 0.4% | +2.6% |